Exploring the Epidemiology of Cancer after Solid Organ Transplantation (EpCOT): an observational cohort study

Introduction Solid organ transplant patients are counselled regarding increased risk of cancer (principally due to their need for lifelong immunosuppression) and it ranks as one of their biggest self-reported worries. Post-transplantation cancer is common, associated with increased healthcare costs and emerging as a leading cause of post-transplant mortality. However, epidemiology of cancer post-transplantation remains poorly understood, with limitations including translating data from different countries and national data being siloed across different registries and/or data warehouses. Methods and analysis Study methodology for Epidemiology of Cancer after Solid Organ Transplantation involves record linkage between the UK Transplant Registry (from NHS Blood and Transplant), Hospital Episode Statistics (for secondary care episodes from NHS Digital), National Cancer Registry (from cancer registration data hosted by Public Health England) and the National Death Registry (from NHS Digital). Deterministic record linkage will be conducted by NHS Digital, with a fully anonymised linked dataset available for analysis by the research team. The study cohort will consist of up to 85 410 solid organ transplant recipients,who underwent a solid organ transplant in England between 1 January 1985 and 31 December 2015, with up-to-date outcome data. Ethics and dissemination This study has been approved by the Confidentiality Advisory Group (reference: 16/CAG/0121), Research Ethics Committee (reference: 15/YH/0320) and Institutional Review Board (reference: RRK5471). The results of this study will be presented at national and international conferences, and manuscripts with results will be submitted for publication in high-impact peer-reviewed journals. The information produced will also be used to develop national evidence-based clinical guidelines to inform risk stratification to enable risk-based clinical follow-up. Trial registration number NCT02991105.

[1]  L. Magder,et al.  Cancer‐attributable mortality among solid organ transplant recipients in the United States: 1987 through 2014 , 2019, Cancer.

[2]  Katherine E Henson,et al.  Data Resource Profile: National Cancer Registration Dataset in England , 2019, International journal of epidemiology.

[3]  A. Teixeira-Pinto,et al.  Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. , 2019, Journal of the American Society of Nephrology : JASN.

[4]  R. Steenkamp,et al.  Chapter 5 Survival and Cause of Death in UK Adult Patients on Renal Replacement Therapy in 2016: National and Centre-specific Analyses , 2018, Nephron.

[5]  B. Kasiske,et al.  Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice , 2017, Transplantation.

[6]  S. Kim,et al.  Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  A. Green,et al.  Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta‐Analysis , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  A. Keogh,et al.  Iatrogenic immunosuppression and risk of non‐Hodgkin lymphoma in solid organ transplantation: A population‐based cohort study in Australia , 2016, British journal of haematology.

[9]  Albert Lee ‘Bolam’ to ‘Montgomery’ is result of evolutionary change of medical practice towards ‘patient-centred care’ , 2016, Postgraduate Medical Journal.

[10]  A. Keogh,et al.  High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. , 2016, Journal of the American Academy of Dermatology.

[11]  A. Sharif,et al.  Cancer‐related outcomes in kidney allograft recipients in England versus New York State: a comparative population‐cohort analysis between 2003 and 2013 , 2016, Cancer medicine.

[12]  S. Kim,et al.  Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada. , 2016, JAMA oncology.

[13]  Anirudh Rao,et al.  UK Renal Registry 18th Annual Report (December 2015) Chapter 5: Survival and Causes of Death in UK Adult Patients on Renal Replacement Therapy in 2014: National and Centre-specific Analyses , 2016, Nephron.

[14]  E. Geissler Post-transplantation malignancies: here today, gone tomorrow? , 2015, Nature Reviews Clinical Oncology.

[15]  E. Engels,et al.  Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis , 2015, Cancer medicine.

[16]  A. Wiseman Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[17]  R. Pfeiffer,et al.  Association of Antibody Induction Immunosuppression With Cancer After Kidney Transplantation , 2015, Transplantation.

[18]  G. Danan,et al.  Tacrolimus and the Risk of Solid Cancers After Liver Transplant: A Dose Effect Relationship , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  A. Courtney,et al.  The Clinical Course of Kidney Transplant Recipients After 20 Years of Graft Function , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  A. Sharif Sirolimus after kidney transplantation , 2014, BMJ : British Medical Journal.

[21]  A. Sharif,et al.  Malignancy-related mortality following kidney transplantation is common. , 2014, Kidney international.

[22]  M. Guba,et al.  Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[23]  D. Brennan,et al.  Selection of induction therapy in kidney transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[24]  A. Keogh,et al.  De novo Cancer‐Related Death in Australian Liver and Cardiothoracic Transplant Recipients , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  Hermann Brenner,et al.  Kidney Graft Survival in Europe and the United States: Strikingly Different Long-Term Outcomes , 2013, Transplantation.

[26]  J. Craig,et al.  Important outcomes for kidney transplant recipients: a nominal group and qualitative study. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  M. Tonelli,et al.  Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation. , 2012, The New England journal of medicine.

[28]  A. Israni,et al.  Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.

[29]  J. Neuberger,et al.  Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  A. Webster,et al.  Long-term cancer risk of immunosuppressive regimens after kidney transplantation. , 2010, Journal of the American Society of Nephrology : JASN.

[31]  SUPPORTING TABLES,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients. , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  C. Vajdic,et al.  Cancer incidence and risk factors after solid organ transplantation , 2009, International journal of cancer.

[33]  B. Kiberd,et al.  Cancer Mortality in Kidney Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[35]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[36]  C. Parkinson,et al.  Management of solid tumours in organ-transplant recipients. , 2007, The Lancet. Oncology.

[37]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[38]  H. Goldschmidt,et al.  Malignancy in renal transplantation. , 2004, Journal of the American Society of Nephrology : JASN.

[39]  B. Kasiske,et al.  Cancer after Kidney Transplantation in the United States , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[40]  J. Fox,et al.  Contemporary Practice , 1996 .

[41]  F. Luan,et al.  Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  Á. Gutiérrez-Dalmau,et al.  Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients , 2012, Drugs.